Interestingly, while IgG control-treated K14-IL17Aind mice displayed psoriasis-like skin lesions starting at an age of 11 weeks, mice that were treated with anti-IL36R antibodies in parallel developed significantly fewer and less severe lesions, although exhibiting comparable levels of IL-17A overexpression. This evidence concerns the gene IL1RL2 and psoriasis.